Drug Profile
YL 13027
Alternative Names: YL-13027Latest Information Update: 05 Feb 2024
Price :
$50
*
At a glance
- Originator Shanghai Yingli Pharmaceutical
- Developer 280Bio; Shanghai Yingli Pharmaceutical; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Phase I Multiple myeloma; Myelodysplastic syndromes; Pancreatic cancer
Most Recent Events
- 22 Jan 2024 Phase-I clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (PO) (NCT06199466)
- 11 Jan 2024 M.D. Anderson Cancer Center plans a phase Ib trial for Pancreatic cancer (Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06199466, NCI2023-11125)
- 24 Sep 2022 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Recurrent, Second-line therapy or greater) in China (PO) (NCT05457517)